Tositumomab
From Wikipedia, the free encyclopedia
| Image:Tositumomab.png | |
|
Tositumomab
|
|
| Systematic (IUPAC) name | |
| Murine anti-CD20 antibody | |
| Identifiers | |
| CAS number | 192391-48-3 |
| ATC code | ? |
| PubChem | ? |
| DrugBank | BTD00085 |
| Chemical data | |
| Formula | C6416H9874N1688O1987S44 |
| Mol. weight | 143859.7 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Tositumomab is a monoclonal antibody derived from immortalized mouse cells. It is a IgG2a anti-CD20 antibody and is covalently bound to Iodine 131. 131I emits both beta and gamma radiation, and is broken down rapidly in the body.
Clinical trials have established the efficacy of tositumomab in patients with relapsed follicular lymphoma.
It is manufactured by Corixa. It sells in the U.S. under the trade name Bexxar.
 |
This medical treatment article is a stub. You can help Wikipedia by expanding it. |
